Squarepoint’s Corvus Pharmaceuticals CRVS Stock Holding History
Bought
Maintained
Sold
Other funds holding CRVS
Squarepoint's CRVS Position: Q3 2026 in Review
Squarepoint increased its Corvus Pharmaceuticals (CRVS) stake by 194% in Q3 2026, buying an estimated $1.2M and bringing the position to 130,023 shares worth $1.5M. The position accounts for ﹤0.01% of the portfolio, ranked #2428.
Squarepoint first reported a position in CRVS in Q1 2018 and has held it in 18 quarters since. The position peaked at $1.81M in Q1 2026. 177 funds tracked by Wall St. Rank hold CRVS as of Q3 2026.
- Squarepoint held 130,023 shares of Corvus Pharmaceuticals worth $1.5M as of Q3 2026.
- Squarepoint bought 85,818 Corvus Pharmaceuticals shares in Q3 2026, an estimated $1.2M.
- Corvus Pharmaceuticals made up ﹤0.01% of Squarepoint's portfolio in Q3 2026, its #2428 holding.
- Squarepoint first reported a position in Corvus Pharmaceuticals in Q1 2018 and has held it in 18 quarters since.
- Squarepoint's Corvus Pharmaceuticals position peaked at $1.81M in Q1 2026.
- 177 funds tracked by Wall St. Rank held Corvus Pharmaceuticals as of Q3 2026.
Based on Squarepoint's 13F filing for Q3 2026, filed 9 Nov 2026.